A trial of depatuxizumab mafodotin for glioblastoma that has come back (INTELLANCE 2)

This trial looked at depatuxizumab mafodotin (Depatux-M, ABT-414) with or without temozolomide. It was for people with glioblastoma that came back after their first treatment (surgery and or radiotherapy).

It was open to people whose glioblastoma had a larger number of receptors for the protein called epidermal growth factor (EGF).

This trial was open for people to join between 2015 and 2016. The trial team published the results in 2020.